Baseline clinical characteristics in patients with HGBL-DH/TH
| . | Responders (n = 5) . | Nonresponders (n = 10) . |
|---|---|---|
| Age, median (min, max), y | 75 (53, 84) | 74 (27, 85) |
| Age group, n (%) | ||
| <65 y | 2 (40.0) | 3 (30.0) |
| ≥65 to <75 y | 0 (0.00) | 4 (40.0) |
| ≥75 y | 3 (60.0) | 3 (30.0) |
| Diagnosis to first dose, median mo (min, max) | 50.0 (23.6, 86.6) | 11.04 (5.4, 73.2) |
| Prior systemic therapies, n (%)* | ||
| 2 | 1 (20.0) | 3 (30.0) |
| 3 | 1 (20.0) | 5 (50.0) |
| >3 | 3 (60.0) | 2 (20.0) |
| Prior stem-cell transplant, n (%) | 1 (20.0) | 2 (20.0) |
| Prior CAR T-cell therapy | 1 (20.0) | 3 (30.0) |
| Response to most recent line of systemic therapy, n (%) | ||
| Relapse | 2 (40.0) | 2 (20.0) |
| Refractory† | 0 (0.00) | 8 (80.0) |
| Other‡ | 3 (60.0) | 0 (00.0) |
| Second-line International Prognostic Index (IPI)§ | ||
| 0-2 | 2 (40.0) | 3 (30.0) |
| 3-5 | 3 (60.0) | 7 (70.0) |
| . | Responders (n = 5) . | Nonresponders (n = 10) . |
|---|---|---|
| Age, median (min, max), y | 75 (53, 84) | 74 (27, 85) |
| Age group, n (%) | ||
| <65 y | 2 (40.0) | 3 (30.0) |
| ≥65 to <75 y | 0 (0.00) | 4 (40.0) |
| ≥75 y | 3 (60.0) | 3 (30.0) |
| Diagnosis to first dose, median mo (min, max) | 50.0 (23.6, 86.6) | 11.04 (5.4, 73.2) |
| Prior systemic therapies, n (%)* | ||
| 2 | 1 (20.0) | 3 (30.0) |
| 3 | 1 (20.0) | 5 (50.0) |
| >3 | 3 (60.0) | 2 (20.0) |
| Prior stem-cell transplant, n (%) | 1 (20.0) | 2 (20.0) |
| Prior CAR T-cell therapy | 1 (20.0) | 3 (30.0) |
| Response to most recent line of systemic therapy, n (%) | ||
| Relapse | 2 (40.0) | 2 (20.0) |
| Refractory† | 0 (0.00) | 8 (80.0) |
| Other‡ | 3 (60.0) | 0 (00.0) |
| Second-line International Prognostic Index (IPI)§ | ||
| 0-2 | 2 (40.0) | 3 (30.0) |
| 3-5 | 3 (60.0) | 7 (70.0) |
N = 15. Data cutoff was 1 March 2021. Median (range) follow-up for the entire LOTIS-2 population: 7.8 (0.3-31.0) months.
Prior stem cell transplant is included. For patients who received an autologous transplant, the mobilization regimen was considered a line of therapy if it was chemotherapy based and distinct from the other previous lines of treatment.
Defined as no response to therapy.
Defined as unknown, not evaluable, or missing.
Derived from baseline values at the time of clinical trial enrollment, as previously described.19 One patient with bulky disease was included in the nonresponder group.